Amarin Corporation plc AMRN was a big mover last session, as the company saw its shares rise nearly 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up 16.4% in the past one-month time frame.
The company has seen two negative estimate revisions in the past few months, while its Zacks Consensus Estimate for the current quarter has also moved lower over the past few months, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward, to see if this recent move higher can last.
Amarin Corporation currently has a Zacks Rank #4 (Sell) while its Earnings ESP is 0.00%.
Amarin Corporation PLC Price
Amarin Corporation PLC Price | Amarin Corporation PLC Quote
A better-ranked stock in the Medical sector is Akari Therapeutics, Plc AKTX, which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is AMRN going up? Or down? Predict to see what others think: Up or Down
Zacks’ Best Private Investment Ideas
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors.
Click here for Zacks' private trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Amarin Corporation PLC (AMRN) : Free Stock Analysis Report
Akari Therapeutics PLC (AKTX) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research